


Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19

July 15 2021



Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID

The lack of sequencing of SARS-CoV-2 variants by the U.S. and other

countries is imperiling the global response to the COVID-19 pandemic, argues Dana Crawford of Case Western Reserve University in a new Viewpoint published July 15th in the journal *PLOS Genetics*.

Surveillance is essential to a successful and rapid response to [disease outbreaks](#), but [public health surveillance](#) has traditionally focused on monitoring case numbers, hospitalizations and deaths. Advances in genome sequencing now allow us to track [genetic variation](#) in evolving viruses in unprecedented detail. However, despite the availability of sequencing in several countries, the adoption of genomics as a strategy for surveilling the SARS-CoV-2 virus, which causes COVID-19, has been slow, difficult and inconsistent. Crawford points out that, as of early April 2021, the U.S. ranked 33rd in the world in SARS-CoV-2 sequencing for variant surveillance. She says that historically, the Centers for Disease Control and Prevention (CDC) has not prioritized genomic research for public health, and this bias has created a gaping hole in our understanding of the real-time evolution of SARS-CoV-2 and the impact on [disease transmission](#) and severity.

Crawford cites insufficient funding, the lack of an effective sample tracking system and strict regulations on sample and data sharing as the causes of the inadequate sequencing efforts. Still, other countries, such as China and the U.K., have successfully overcome these challenges. The CDC recently committed more than \$200 million to enhance sequencing, but Crawford points out that this late investment means that the U.S. lacks an organized database of patient information for COVID-19 studies. She cautions that investments in SARS-CoV-2 genomics need to continue and expand as new variants will likely arise due to variability in vaccination rates and adherence to COVID-19 precautions worldwide.

Given that SARS-CoV-2 is a novel zoonotic disease with no prior human infections, Crawford argues that sequencing and analysis are vital to

understanding both the trajectory of the outbreak and its evolution. Provisions are also sorely needed to link genetic data to clinical and epidemiological data sources for public health research. Finally, she concludes that ongoing international sequencing efforts are still needed to understand and respond to this continually evolving virus that knows no international boundaries.

"COVID-19 control requires near real-time host-pathogen genomic and public health data to track how SARS-CoV-2 has evolved and how this evolution affects transmission and disease severity," Crawford adds. "US and global sequencing efforts have been too few and too disjointed, underscoring the need to engage with human genomics and integrate its technologies in emerging infectious disease [public health](#) responses."

More information: Crawford DC, Williams SM (2021) Global variation in sequencing impedes SARS-CoV-2 surveillance. *PLoS Genet* 17(7): e1009620. doi.org/10.1371/journal.pgen.1009620

Provided by Public Library of Science

Citation: Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19 (2021, July 15) retrieved 27 April 2024 from <https://medicalxpress.com/news/2021-07-inadequate-sequencing-sars-cov-variants-impedes.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--